BofA Securities recently downgraded PROCEPT BioRobotics from Buy to Neutral, citing slowing utilization growth and moderating system sales for its Aquablation technology amid tighter hospital capital ...

Procept BioRobotics' surgical bots tackle a perplexing prostate problem, boosting the San Jose company's financial results. Newly approved cancer drug lands $8 ...

PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation ...

The demand for robotics and automation continues to grow, particularly following the pandemic. As labor costs have escalated, companies have invested in labor-saving measures. Market forecasts project ...

In the Europe-wide FIThydro project, TalTech researchers worked with industry partners to study existing hydroelectric power plants. Together with researchers across Europe, they developed new ...

Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024 U.S. handpiece and consumables revenue of $43.1 million for the second ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Morgan Stanley on December 2, 2025. The analyst firm set a price target for $51.00 expecting PRCT to rise to within 12 ...

Chicago Capital disclosed a buy, raising its Procept BioRobotics stake to 1.38% of 13F AUM. Top holdings for Chicago Capital after the filing are: META: $214.48 million (5.3% of AUM) GOOGL: $171.23 ...

Total revenue for the first quarter of 2025 was $69.2 million, an increase of 55% compared to the prior year period. U.S. revenue was $60.3 million, representing growth of 50% compared to the prior ...